There are currently 537 clinical trials in Denver, Colorado looking for participants to engage in research studies. Trials are conducted at various facilities, including Colorado Blood Cancer Institute, National Jewish Health, Rose Medical Center and Porter Adventist Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
NCT04469439
Recruiting
This study will be a prospective, observational study of patients who undergo endoscopic sinus surgery for cystic fibrosis-related chronic rhinosinusitis (CRS). Individuals who do not undergo surgery but are treated medically for CRS will also be enrolled to serve as a control group. Outcomes analyzed will include pulmonary, quality of life, and others.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/23/2025
Locations: National Jewish Health, Denver, Colorado
Conditions: Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: National Jewish Health, Denver, Colorado
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
NCT05469893
Recruiting
The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatmen... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma
Register for Updates
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795
Recruiting
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/21/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado
Conditions: Locally Advanced or Metastatic Solid Tumors
Register for Updates
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT04576104
Recruiting
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: University of Colorado, Denver, Colorado
Conditions: Endometrial Carcinoma, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Register for Updates
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
NCT05585320
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
Register for Updates
VISN 19 MIRECC Research Database
NCT01334476
Recruiting
The VISN 19 MIRECC is involved in research concerned with suicide prevention in high risk populations (e.g., history of traumatic brain injury, post-traumatic stress disorder); Recruitment for future studies will continue with a similar focus. The aim of this protocol is for the VISN 19 MIRECC Research Database (V19-MRD), to have a data repository of participants for possible recruitment from other studies being conducted at the VISN 19 MIRECC. The VISN 19 MIRECC conducts numerous research proje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: VA Eastern Colorado Health Care System, Denver, Colorado +1 locations
Conditions: Demographic Data, History of Medical and Mental Health, History of Combat Experience, History of Suicide, Imaging Results
Register for Updates
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657
Recruiting
The main purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness (ability to treat your cancer) of REGN5678 alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in com... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Sarah Cannon Research Institute (SCRI), Denver, Colorado
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Register for Updates
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146
Recruiting
This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Research Site, Denver, Colorado
Conditions: Solid Tumors
Register for Updates
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Sarah Cannon Research Institute at HealthOne, Denver, Colorado
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates
Testing the Engaged Approach to Lung Cancer Screening
NCT06327074
Recruiting
The goal of this study is to assess feasibility and acceptability of the Engaged Approach to Lung Cancer Screening (EA-LCS) in diverse lung cancer screening (LCS) programs operating in a variety of geographic regions across Colorado and the US.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Colorado Hospital, Denver, Colorado
Conditions: Lung Cancer
Register for Updates